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Abstract: The personalized medicine is an emergent and rapidly developing method of clinical practice 
that uses new technologies to provide decisions in regard to the prediction, prevention, diagnosis and 
treatment of disease. A continuous evolution of technology and the developments in molecular diagnos-
tics and genomic analysis increased the possibility of an even more understanding and interpretation of 
the human genome and exome, allowing a “personalized” approach to clinical care, so that the concepts 
of “Systems Medicine” and “System Biology” are actually increasing. The purpose of this study is to 
evaluate the personalized medicine about its indications and benefits, actual clinical applications and fu-
ture perspectives as well as its issues and health care implications. A careful review of the scientific lit-
erature on this field that highlighted the applicability and usefulness of this new medical approach as 
well as the fact that personalized medicine strategy is even more increasing in numerous fields of appli-
cations. 
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INTRODUCTION 
 “Personalized medicine” is a generic term, without a 
clear definition, used in numerous different meanings that 
often disagree about its real meaning [1]. Therefore, it is 
necessary to first analyze the explanations on this topic re-
ceived from the highest positions in Europe and USA. 
 According to the European Parliamentary Research Serv-
ice (EPRS 2015), it refers to an “emerging – evolving ap-
proach to medicine” that uses scientific insights into the ge-
netic and molecular basis of health and disease brought on 
by the sequencing of the human genome, to guide decisions 
in regard to the prediction, prevention, diagnosis and treat-
ment of disease. Therefore, the aim of the Personalized 
Medicine is generally perceived to be the “right treatment for 
the right person at the right time” [2]. 
 Similarly, the National Cancer Institute (NIH) underlined 
the three main purposes of the Personalized Medicine: to 
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prevent, to diagnose and to treat disease, using specific in-
formation about genes, proteins and environment of each 
patient [3]. 
 Furthermore, the President’s Council of Advisors on Sci-
ence and Technology – Executive Office of the President of 
the United States – with a report on September 2008, has 
specified that the term Personalized Medicine “does not lit-
erally mean the creation of drugs or medical devices that are 
unique to a patient, but rather the ability to classify individu-
als into subpopulations that differ in their susceptibility to a 
particular disease or their response to a specific treatment. 
Preventive or therapeutic interventions can then be concen-
trated on those who will benefit, sparing expense and side 
effects for those who will not” [4]. 
 The continue evolution of technology and the develop-
ments in molecular diagnostics and genomic analysis in-
creased the possibility of an even more understanding and 
interpretation of the human genome and exome, allowing a 
“personalized” approach to clinical care. The medicine has 
attempted for a long time to reach this objective and the pro-
gress in the genomic field promises to facilitate this trial. In 
fact, the possibility of identifying the individual susceptibil-
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ity to certain diseases and responses to therapy is the neces-
sary step to properly implement the best strategy for disease 
prevention and care with a treatment that meet the individual 
needs and characteristics of each patient [5, 6]. 
 We currently have different typologies of genetic tests: 
molecular tests analyze genes and short lengths of DNA; 
chromosomal tests study the whole chromosomes and long 
lengths of DNA; biochemical tests study the amount and the 
activity level of proteins. Moreover, the implementation of 
whole-exome sequencing – chipper than whole-genome se-
quencing – that analyzes selectively coding regions, is used 
to discover rare coding variants and then to identify both 
common and rare genetic disease. Metabolomics (study of 
the metabolome: all of metabolites in an organism), pharma-
cogenomics (interaction between drug and individual genetic 
make-up), transcriptomics (quantitative study of all genes in 
an organism) and proteomics (analysis of proteome: the en-
tire collection of proteins in an organism, tissue type or cell) 
play an even more relevant role in personalizing medicine. 
All these tests, analyzing human DNA, RNA and proteins, 
can identify variations, mutations, gene variants, genetic 
anomalies and metabolic profiles that are associated with 
certain diseases and that can influence the therapy response. 
In this way, they can interfere in all of the phases of disease: 
susceptibility and risk factors, preclinical progression, diag-
nosis, disease progression and therapy, being able to recog-
nize different types of tests applicable in clinical practice, 
such as diagnostic testing (to identify a disease and to assist 
in clinical decision-making), predictive testing (to calculate 
the likelihood of developing a disease), carrier testing (to 
understand the likelihood of passing a genetic disease to a 
child), prenatal testing (to identify disease in a fetus), new-
born screening (to determine if a newborn has a disease 
known to cause problems in health and development), phar-
macogenomics testing (to determine the optimal drug ther-
apy and dose given a person’s metabolic response) and re-
search testing (to contribute to understanding of underlying 
cause of disease) [7-9]. 
 This new approach to medicine, based on emerging tech-
nologies and sciences, has changed the medical practice and 
consequently the health care system. The possibility to pre-
dict and to intervene before damage, has transformed the 
reactive health care system, based on the treatment of dis-
eases, in a “prospective health care” system, focused on pre-
vention and treatment of diseases in relationship with a per-
sonalized risk. Analyzing scientific literature, it can be 
shown that the concepts of “Systems Medicine” and “System 
Biology” are actually increasingly. In fact, the new trend of 
particular interest is the so-called “P4 systems medicine”: 
Predictive, Preventive, Personalized and Participatory, con-
cept pursued by the oncologist Leroy Hood since 2011 [10]. 
It gives up the reductionist medicine to embrace a revolu-
tionary holistic approach aimed at healthcare optimization, 
focusing on the interactions of a biological system and study-
ing the whole life process from the molecular to the social 
[11]. 
 In the last decades, numerous risk loci for common and 
rare diseases have been identified and discovered many ge-
netic variants that influence the action of pharmacologic 
agents. But, with the evolution of these sciences, the drop in 
the cost of sequencing (especially whole-exome) and the 
availability of numerous databases, the number of studies 
and publications on this topic have been increased in the last 
years. Therefore, it is relevant to recognize the clinical appli-
cability and the healthcare implications of this new biomedi-
cal approach as well as its limits, to better understand how to 
improve its usage in the future [12]. 
CLINICAL APPLICATIONS AND FUTURE PER-
SPECTIVES OF PERSONALIZED MEDICINE 
 Nowadays, the personalized medicine strategy is increas-
ing in numerous fields of applications, thus revolutionizing 
the medical practice. To understand its real impact to clinical 
practice, firstly it is necessary to dissect the main clinical 
areas of interest, focusing the attention on the actual findings 
and usage of each of them and the future perspectives. 
ONCOLOGY 
 The oncology is the most commonly interested area by 
the personalized medicine on the basis of the same nature of 
the cancer. In fact, cancer is a complex disease characterized 
by the accumulation of mutations occurring in critical genes 
and resulting in the alteration of molecular paths. The appli-
cation of genetic tests in oncology involves both healthy and 
sick persons: the first one, may benefit from screening tests 
that can identify the risk of developing some disorders; the 
second one, can be benefitted by the best therapeutic strat-
egy, thanks to the molecular characterization of the cancer 
that allows new knowledge into the prediction of the disease 
progression and in response to the treatment for each patient. 
Hereditary cancers are about 10-15% of total cancer but 
many studies of the human genome have allowed to deter-
mine the risk of cancer and to discover the prognostic and 
predictive biomarkers. Furthermore, some genetic variants of 
genes were discovered that metabolize drugs, allowing to 
understand the toxicity of specific drugs and the response to 
therapy [13]. Nowadays, the association between genomic 
variations with different cancers, such as the BRCA 1 and 2 
and PARP genes in breast cancer tumors, ERBB2 receptor in 
breast adenocarcinoma, BCR/ABL fusion gene in chronic 
myelogenous leukemia, BRAF (V600E) in melanoma, colo-
rectal and thyroid cancer, is well established. Furthermore, 
genetic tests provide a number of information about the best 
therapy allowing a target therapy: examples are the usage of 
Herceptin in female breast cancer patients with HER-2 ex-
pression, the Imatinib that targets the BCL/ABL, the Vemu-
rafenib targeting BRAF in melanoma or the usage of 
Gleevec to inhibit tyrosine kinase in chronic myleloid leu-
kemias.  
 Considering that all types of tumor cannot be described 
in detail in a single article, we have chosen to summarize in 
Table 1 the variants with greater scientific value found in the 
literature and recognized by the National Institute for Cancer 
[14]. 
 Despite numerous studies have been made, the develop-
ment of new genetic variants is still in progress. The possi-
bility to search within each tumor the actionable/druggable 
alteration using new technologies opens the way to Personal-
ized Medicine in the field of oncology [15, 16]. 
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Table 1. Targeted therapies approved by the FDA for the treatment of some types of cancer. Several targeted therapies have been 
approved to treat more than one type of cancer. 
Gene Tumor Type Targeted Agent 
HER2 Breast cancer and gastric cancer Trastuzumab 
BRAF Melanoma, colorectal cancer and thyroid cancer Vemurafenib 
BCR-ABL Chronic myleloid leukemia, GIST and myeloproliferative disorders Imatinib 
KDR Gastric cancer, colorectal cancer and lung cancer Ramucirumab 
SMO Basal cell carcinoma Vismodegib, Sonidegib 
CD274 Bladder cancer Atezolizumab 
VEGF Brain cancer, cervical cancer, colorectal cancer, kidney cancer, lung cancer, ovarian epithelial cancer, 
fallopian tube cancer and primary peritoneal cancer 
Bevacizumab 
MTOR Brain cancer, breast cancer, kidney cancer and pancreatic cancer Everolimus 
HER1/HER2 Breast cancer Lapatinib 
HER2 Breast cancer Pertuzumab 
CDK4/CDK6 Breast cancer Palbociclib 
EGFR Colorectal cancer, head and neck cancer Cetuximab 
EGFR Colorectal cancer Panitumumab 
PDCD1 Kidney cancer, lung cancer, lymphoma and melanoma Nivolumab 
MS4A1 Leukemia and lymphoma Rituximab 
BCR-ABL Leukemia Dasatinib 
CD52 Leukemia Alemtuzumab 
EGFR Lung cancer Gefitinib 
EGFR Lung cancer and pancreatic cancer Erlotinib 
CD38 Multiple myeloma Daratumumab 
 
PSYCHIATRY AND “P5 MEDICINE SYSTEM” 
 The psychiatric diseases are multifactorial pathologies 
and already validated the influence of genetic in some of 
them. Ozomaro et al. pointed out as several studies demon-
strated the correlation between genetic alterations and some 
disorders: schizophrenia is one of the disorders most influ-
enced by genetic with a risk of heritability of 50 to 80%, the 
genetic risk of the major depressive disorder is estimated in a 
range of 40-70%, and also the bipolar disorder is highly heri-
table, with genetic variables estimated for 60 to 85% of risk 
[17]. Nevertheless, psychiatric diseases today are diagnosed 
by symptoms and psychopathological tests with a categorical 
approach summarized in the criteria from the Diagnostic and 
Statistical Manual of Mental Disorders (DSM). But a new 
approach in the field of psychiatric disorders diagnosis was 
proposed by Bragazzi that suggested to apply omics science 
in psychiatry. This approach, based on the fact that psychiat-
ric disorders share biological background and environmental 
exposures, can allow a further evolution of the P4 medicine 
introducing a new domain: the Psycho-cognitive one. So, it 
could switch to the new P5 medicine system in which psy-
chological health is seen as an essential aspect of personal 
well-being [18]. Numerically increasing, the P is required by 
many different disciplines, keeping in view the further added 
value of "Protection (P5)", therefore, invoking the need for 
the patient to be protected and then a conceptual system to be 
understood as equity in distribution of resource and free ac-
cess to personalized medicine.  
 This new system is obviously extended to the usage of 
omics in evaluation of treatment response. In fact, Shaunna 
L. Clark at al. in 2011, and Daniel E. Adkins et al. in 2013, 
with an analysis made using data from CATIE (Clinical An-
tipsychotic Trials of Intervention Effectiveness) and 
STAR*D (Sequenced Treatment Alternatives to Relieve De-
pression) [19, 20], proved the correlation between genotype 
background and efficacy and effects of the treatment. There-
fore, their results highlighted the potential to personalize 
antipsychotic treatment and the importance of identifying 
predictors of drug response [21, 22]. In fact, in addiction to 
numerous studies about the well-known Cytochrome P450, 
other gene associations have been studied to evaluate the 
antidepressant treatment response, such as SLC6A4 and 
FKBP5 involved in glucocorticoid trafficking, HTR2A that 
encodes a serotonin 2A receptor [23], ABCB1 that encodes a 
p-glycoprotein that affects brain concentrations of some an-
tidepressants [24], CYP2D6*4 polymorphism influencing on 
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dose, switching and discontinuation of antidepressants [25]. 
Moreover, many studies highlighted the correlation between 
some antipsychotic drugs and adverse reactions [26-29]. All 
these results are shown in Table 2. 
 However, many results of these analyses are waiting for a 
replication in largest samples [30]. 
 These findings suggest that much more can be done in 
the field of personalized psychiatry to improve both diagno-
sis method and treatment strategy with a great impact on 
medical practice and patient well-being. A more precise and 
effective therapy, can and should be there for the sick person 
and patients should be involved in decision-making, and be 
fully informed about the treatment. 
NEUROLOGY 
 The role of genes has been associated with some neuro-
logical diseases, such as, for examples: Duchenne Muscular 
Dystrophy, a recessive X-linked disease; Alzheimer’s Dis-
ease, a degenerative brain disease which are not clearly un-
derstood because the genes may play an important role in the 
development of disease (among the numerous genes identi-
fied are the APP, the PSEN1, the PSEN2 and the APOE). 
Parkinson’s Disease is a complex neurological disorder that, 
even if it is not a genetic disease, it has a family history in 
15% of individuals, possibly caused by mutations in LRRK2, 
PARK2, PARK7, PINK1 or SNCA genes or by alterations in 
genes not yet identified. Epilepsy, another complex neuro-
logical disorder with numerous causes of brain dysfunction 
where, in majority of the cases, there is an interaction be-
tween multiple genes and environmental factors, while in 1-
2% of cases a single gene defect (SCN1A and PCDH7 genes 
are associated with an increase disease risk) is recognized. 
These disorders, characterized by a great heterogeneity and 
variability in susceptibility, causation, clinical profiles and 
drug response, are an optimal target for the usage of omics 
sciences and many clinical institutes have already considered 
the routinely usage of genetic technologies to select the best 
treatment for a single patient. In fact, being these neurologi-
cal diseases chronic and irreversible, the opportunity to know 
the drug response plays a very important role: it could lead to 
new treatment frameworks with a better effectiveness and 
reduced side effects and it can completely change the lives of 
the patients suffering from these diseases. Unfortunately, 
genomics knowledge in this field is still limited and clinical 
trials are limited by the lack of DNA data collections, long 
times and elevated costs [31, 32]. 
CARDIOVASCULAR DISEASES 
 Many studies reported that the variation in clinical car-
diovascular diseases (CVDs) depend on heritable factors and 
its risk factors. Examples are a familial predisposition of 
myocardial infarction, atrial fibrillation, and congestive heart 
failure. Moderate heritability conditions include coronary 
artery calcification, blood pressure, total cholesterol, and 
body mass index. The American Heart Association reviewed 
genomic epidemiology by three categories of cardiovascular 
condition: atherosclerosis and myocardial infarction, ele-
vated cholesterol and other lipid disorders, and blood pres-
sure and hypertension. The National Heart, Lung, and Blood 
Institute of USA summarized possible genetic contributors 
related to risk of coronary heart disease. Many kinds of 
genes considered mostly likely to potentially contribute to-
ward an increased risk of coronary heart disease. The main 
application of clinical genomic in this field is the study about 
the influence of genes in drug response. Examples of bio-
markers and genetic tests used in cardiovascular disease are 
summarized in Table 3 [33-46]. 
 Recently, different authors studied the applications of 
pharmacogenomics in the most common antiplatelet (clopi-
dogrel and aspirin) and anticoagulation (warfarin) therapy. 
They proved as the genetic variants are important determi-
nants of antiplatelet and anticoagulation therapy response 
and then that the application of pharmacogenetic can provide 
important information to assist clinicians with prescribing 
the most personalized and effective antiplatelet and antico-
agulation therapy. Thus, a future view is to apply this knowl-
edge for the next-generation antiplatelet (prasugrel and tica-
grelor) and anticoagulant (dabigatran) agents on the fact that 
a genetic susceptibility also is recognized for them [47-49].  
 A big limitation of the use of personalized medicine in 
this field is that, despite multiple studies have been per-
formed, the results of literature are discrepant and inconclu-
sive in some instances. This might be due to inadequately 
powered studies, studying the different drug response pheno-
types or patient populations (differences in allele frequen-
cies), problems precisely measuring the phenotype, subtlety 
of functional effects of polymorphisms, focus on single 
SNPs instead of haplotypes, and failure to consider the com-
plexity of drug response [50]. For example, response to cur-
rently used antiarrhythmic therapies is notoriously variable, 
with some patients deriving clear cut benefit, such as reduc-
tion in episodes of paroxysmal atrial fibrillation, while other 
derive no benefit or even develop new arrhythmias, such as 
diLQTS. Some variability in response to antiarrhythmic drug 
therapy, as in variability in response to many other forms of 
pharmacologic therapy, can be attributed to variable drug 
disposition. For example, loss-of-function variants in 
CYP2D6, encoding a hepatic cytochrome P450 responsible 
for metabolism of approximately of 25% of clinically used 
drug [51]. Therefore, being recognized as the great potential 
to personalized medicine in this field, more studies are 
needed to a better understanding and standardization of re-
sults. 
CHRONIC CONDITIONS, METABOLOMICS PRO-
FILE AND PERSONALIZED LIFESTYLE MEDICINE 
 It is known that chronic and lifestyle-induced conditions, 
such as metabolic syndrome, type 2 diabetes, cardiovascular 
diseases and obesity, are correlated with a high rate of hospi-
talization. In particular, coronary heart disease and type 2 
diabetes (preventable chronic diseases) are leading causes of 
morbidity and mortality in the United States [52]. 
 Many studies have already demonstrated the impact of 
genes in Diabetes Mellitus and its risk factors as well as the 
interactions between genetic make-up and response to diet 
and dietary changes, both in terms of predisposing to devel-
opment of obesity, metabolic syndrome and Diabetes Melli-
tus 2, and in determining responsiveness to specific dietary 
changes. 
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Table 2. Role of genetic testing in Psychiatry: fields of application and impact on clinical practice. 
Genetic Testing Applications Impact on Clinical Practice 
ABCB1 gene Antidepressant treatment Prediction of responsiveness to certain antidepressants 
CYP2D6 gene Antidepressant and antipsychotic treatment 
Evaluation of drug metabolism 
Assessment of dose requirement 
HTR2A gene Antidepressant treatment Prediction of responsiveness to citalopram administration 
CYP2C9 gene Antidepressant, antipsychotic and anticonvulsant treatment Evaluation of drug metabolism 
CYP2C19 gene Antidepressant, antipsychotic and anticonvulsant treatment Evaluation of drug metabolism 
HLA-A gene Anticonvulsant treatment 
Evaluation of risk of carbamazepine hypersensitivity  
syndrome 
ABCC2 gene Anticonvulsant treatment 
Assessment of the probability of neurological adverse drug 
reactions from taking carbamazepine 
CREB1 gene Antidepressant treatment 
Prediction of treatment related suicidal ideation with  
citalopram 
Kainate type ionotropic 
glutamate receptor 4 
(GRIK4) gene 
Antidepressant treatment Prediction of responsiveness to citalopram 
RGS2 gene Antipsychotic treatment Prediction of risk of antipsychotic induced parkinsonism 
PON1 gene Antipsychotic treatment 
Assessment of the probability of weight gain from taking 
risperidone 
NPY1R gene Antipsychotic treatment 
Assessment of the probability of weight gain from taking 
risperidone 
Glutamate decarboxylase 
like 1 (GADL1) gene 
Affective disorders treatment Prediction of responsiveness to lithium 
 
Table 3. Biomarkers and genetic tests used in cardiovascular disease. 
Genetic Testing Application Impact on Clinical Practice 
Natriuretic peptide precursor A (NPPA) 
gene 
Antihypertensive therapy 
Prediction of responsiveness to diuretic versus calcium channel blocker 
treatment 
CACNA1D gene Antihypertensive therapy Prediction of responsiveness to certain calcium channel blockers 
LPA gene Antiplatelet treatment 
Prediction of cardiovascular risk and benefits from acetylsalicylic acid ad-
ministration 
Integrin beta 3 precursor (ITGB3) gene Antiplatelet treatment 
Enhanced thrombin formation and impaired antithrombotic action of acetyl-
salicylic acid 
KIF6 gene Lipid lowering treatment Prediction of responsiveness to statin treatment 
Beta 1 adrenergic receptor (ADRB1) 
gene 
Antihypertensive therapy Prediction of antihypertensive response to metoprolol 
CYP2D6 gene Antihypertensive therapy Identification of poor metabolizers that are at increased risk of bradycardia 
CYP2C19 gene Antiplatelet treatment Characterization of responsiveness to clopidogrel administration 
ACE gene Antihypertensive therapy Prediction of effectiveness of ramipril administration 
Solute carrier organic anion transporter 
family member 1B1 (SLCO1B1) gene 
Lipid lowering treatment Assessment of statin induced myopathy risk 
 
(Table 3) Contd…. 
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Genetic Testing Application Impact on Clinical Practice 
HMGCR gene Lipid lowering treatment Prediction of responsiveness to pravastatin administration 
CYP2C9 gene Anticoagulant treatment Evaluation of warfarin metabolism 
VKORC1 gene Anticoagulant treatment 
Prediction of warfarin dose requirement 
Evaluation of warfarin resistance 
Familion 5-gene profile 
Prevention and treatment of 
cardiac channelopathies 
Drug selection in patients with cardiac channelopathies such as LQTS 
Niemann-Pick CI Like I (NPCILI) 
haplotype 
Lipid lowering treatment Prediction of benefits from ezetimibe administration 
Apolipoprotein A5 (ApoA5) genotype Lipid lowering treatment Prediction of effectiveness of fenofibrate administration 
 
 But the future for these particular conditions, character-
ized by a particular variability, is the progress in omics sci-
ences. Shuzhao Li et al., in a recent review of the latest pro-
gress in blood transcriptomics and metabolomics, high-
lighted how these new omics technologies can be the key to 
fill the gap between genomics and phenotypes. They stressed 
the role of metabolomics, a fast-growing technology that 
captures both endogenous metabolites and environmental 
exposures, for diseases markers. Some examples of me-
tabolomics for biomarker study are presented, such as for 
diabetes (metabolite markers of diabetes were reported many 
years prior to the disease onset), nonalcoholic fatty liver dis-
ease, asthma, macular degeneration, Parkinson’s disease, and 
tuberculosis. The particularity of metabolomics is that it can 
match data from other omics technologies allowing the iden-
tification and quantitation of specific metabolites. S. Li et al. 
and K. Beebe and A. D. Kennedy, in their studies, showed 
how a single blood and/or urine sample submitted for a me-
tabolomics screen can monitor, quickly and at the same time, 
a multitude of genetic anomalies, suggesting that me-
tabolomics can be considered a potential alternative to clini-
cal blood tests. They, moreover, observed that, with an im-
plementation of metabolomics technology, it could be ex-
pected to quantify over 1000 chemicals in less than 10 min, 
changing at all diagnostic procedures and the clinical prac-
tice. Therefore, transcriptomics and metabolomics data from 
large cohorts can lead to robust models of risk factors and 
disease mechanisms, helping to better phenotype patients 
and predict their responses to drugs [53-55]. 
 These finding are well applicable to improve lifestyle. 
A.A. Vorderstrasse et al. applied this concept in their work 
showing as the knowledge of risk factors before manifesta-
tion of disease can help patient to improve the adherence in 
several modifications of lifestyle (such as diet, physical ac-
tivity and smoking cessation) that may reduce individual 
susceptibility to some condition [52]. 
 Here is the other future possibility of personalized medi-
cine: the personalized lifestyle medicine, a system of medi-
cine that merges technological advances with the traditional 
foundation of lifestyle through the psychosocial-behavioral 
interface [56]. 
 The strategy works successfully and is strictly guided by 
the “precaution principle” which guarantees safe and appro-
priate use of genomic data. The workflow is illustrated be-
low in Figs. (1-3). 
 
 
 
Fig. (1). Clinical applications and principal fields of interest. 
 
PERSONALIZED MEDICINE ISSUES AND 
HEALTHCARE IMPLICATIONS 
 The global impact of personalized medicine is constantly 
growing in the last years. Charles Auffray et al. (2016) 
showed the increasing applications of human genetics into 
public health programs and that numerous initiatives are
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Fig. (2). Workflow in oncology illustrating strategy of safe and appropriate use of genomic data, strictly guided by the “precaution principle”. 
 
 
 
Fig. (3). Workflow in psychiatry illustrating strategy of safe and appropriate use of genomic data, strictly guided by the “precaution princi-
ple”. 
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made around the world to implement clinical genomic, such 
as the Welcome Trust Deciphering Developmental Disorders 
(WTDDD) in Europe and the National Human Genome Re-
search Institute Centers for Mendelian Genomics (NHGRI 
CMG) or The Centers for Disease Control and Prevention 
(CDC), Advanced Molecular Detection Initiative in USA 
[57]. As a matter of fact, however, its usage is restricted to a 
small portion of patients, primarily for the diagnosis of Men-
delian conditions and for cancer treatments. 
 One of the biggest difficulties that, still today, limits the 
use of PM and, above all, the possibility of even more re-
searches in this field, is the management of the big-data. This 
issue includes: data storage and processing, data integration 
and interpretation, generation of cost-effective of big-data 
and individual and global cost relevance. The main problems 
that we found include the typical storage of data in a differ-
ent way in different hospitals and the fact that the electronic 
health records (EHRs) do not support formats needed to re-
cord genetic results. These issues extremely limit the stan-
dardization of data, their study and interpretation and then 
their use. In fact, the great contribution of the collecting ge-
netic information into electronic medical records consists in 
the possibility to improve the analysis of data as well as to 
discover the genetic basis of susceptibility to diseases and to 
drug responses. Therefore, it is necessary to upgrade the col-
lection in data-bank of the amount of data generated by new 
technologies; this can be possible only by investing more in 
bioinformatics, biomathematics, and biostatistics [58]. 
 Another big barrier to routine use of PM in clinical care 
is the lack of different types of trials validating the advantage 
of using pharmacogenetic in the different fields of applica-
tion. This prevents the construction of diagnostic and thera-
peutic algorithms for routinely use. 
 In the USA, the same President recently announced a 
Precision Medicine Initiative that aims to accelerate progress 
toward a new era of PM, with a longitudinal “cohort” of 1 
million or more Americans who have volunteered to partici-
pate in research. This initiative has two main components: a 
near-term focus on cancers and a longer-term aim to generate 
knowledge applicable to the whole range of health and dis-
ease [59, 60]. Also, Luxembourg, on May 2015, began an 
electronic health records project with the cooperation of 
some 30,000 patients. 
 Much needs to be done to advance personalized medi-
cine, but many things still have to be defined, especially in 
Europe. In fact, despite the great strides made in the recent 
years, in EU there is still a long way to achieve the goals of 
personalized medicine.  
 The European Alliance for Personalized Medicine, in 
fact, highlighted that economic difficulties for health systems 
in the EU does not mean that patients cannot be helped, and, 
have to bear the high cost of many new drugs. Pricing and 
reimbursement of medicines within the EU is a Member 
State competence and it is the responsibility of the individual 
Member State to use his bargaining power to reduce costs as 
low as possible [61, 62]. 
 Moreover, a personalized approach to health care may be 
limited by the lack of knowledge of many clinicians in inter-
preting and acting on pharmacogenetic information, as well 
as by the patient’s knowledge and level of autonomy. These 
barriers must be removedto allow the pharmacogenetic to 
become a routine part of health care [63]. 
CONCLUSION 
 The challenges of switching from a P4 to a P5 medicine 
to better protect patients and consumers have two issues with 
inescapable dimensions, i.e. technological and societal. The 
first one is evolving, the latter is far more complex [64]. In 
Europe, discussions are currently taking place to reduce ine-
qualities in access to PM. To this end, there are authors who 
warned that the advancement of personalized medicine 
should be based on careful, ethical and responsible research 
[65]. However, beyond this admittedly important objective, 
it is a more general problem of the formation of a more ma-
ture and conscious scientific culture. 
 Personalized medicine is therefore proposing a number of 
social problems that require the development of new proc-
esses of collaborating between patients and researchers. It 
has been pointed out that understanding the public’s percep-
tions, values, and expectations is important given that the 
public is not only its main beneficiary but also its primary 
funder [66]. The real game of personalized medicine is there-
fore played on social comparison, proposing criteria of eq-
uity and distribution of resources that need to be carefully 
evaluated [67]. Education in PM is critical. So the challenge 
will be critical in order to create projects and strategies in 
agreemet to the will of the people and attentive to the needs 
of patients [65]. 
 It is a challenge not easy to win, essential for the optimal 
course of treatment success: mutual understanding and lis-
tening the other’s point of view between doctors and patients 
is needed. Only then, personalized medicine can meet the 
challenge of being a positive development for future medi-
cine [68]. 
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